Developer docs
API playgroundTry for free, no card

Search company profiles

Hyphens Pharma

Full company profile

uuid002jc5t

Namestring
Hyphens Pharma
Legal namestring
Hyphens Pharma Pte Ltd
Websiteurl
hyphens.com.sg
Company typeenum
Public
Founded yearint
1989
Descriptiontext

Hyphens Pharma Pte Ltd is a Singapore-headquartered specialty pharmaceutical group (parent: Hyphens Pharma International Limited; SGX Catalist: 1J5) that operates across 5 directly-served ASEAN markets (Singapore, Malaysia, Vietnam, Indonesia, Philippines) and reaches a further 10 countries via distribution partners, with a field force of approximately 330 sales and marketing professionals. The group runs three business pillars: (i) Specialty Pharma Principals — exclusive distribution, licensing and supply agreements with European and US brand principals (including Bausch+Lomb, Chiesi, Guerbet, HRA Pharma, Lundbeck, MEDICE, Daewoong, and others) covering therapeutic areas such as dermatology, ophthalmology, paediatrics, neonatology, allergy, otorhinolaryngology, orthopaedics and rheumatology, radiology, cardiology, gastroenterology, and child psychiatry; (ii) Proprietary Brands — developed, marketed and sold dermatological products under the Ceradan (including patented Ceradan Advanced pH Management) and TDF Derma Formula lines, scalp-care products under CG 210 (acquired from Legacy Healthcare), and health supplements under Ocean Health, with several technologies (Meradan microemulsion, Xcelarev delivery, Hi-Pure botulinum toxin A) co-developed or licensed with A*STAR; and (iii) Medical Hypermart and Digital — operated through DocMed Technology, supplying pharmaceutical products and medical supplies to healthcare professionals, institutions and retail pharmacies. Founded with early operations in Vietnam in 1989, the group has subsequently expanded to Malaysia (2004), Philippines (2007), Indonesia (2011), and into Middle East markets via a Cooper Pharma partnership for Ceradan in 2024 and an exclusive MC2 Therapeutics licence for Wynzora Cream across ASEAN in 2024. Reported group revenue was SGD 162.3 million in 2022.

The business model combines licensing/royalty economics on distributed principals, branded OTC/Rx product economics on proprietary dermatology and supplement lines, and B2B transaction fees through the DocMed medical hypermart. Go-to-market is enterprise field sales targeting hospitals, clinics, retail pharmacies and healthcare professionals across Southeast Asia, supplemented by exclusive third-party distributors in non-direct markets such as Mainland China, South Korea and the Middle East. Proprietary product differentiation relies on patented formulation technologies, clinical study evidence (e.g., Ceradan Advanced pH-control mechanism, TDF Blu Voile sunscreen cellular-level blue light protection, Meradan co-developed microemulsion), and trademarks granted across multiple jurisdictions. Strategic R&D is conducted through ongoing collaborations with A*STAR (ICES and A*ccelerate units) on microemulsion and dermatological R&D, while licensing-led growth has been the principal route for pipeline additions (Nabota botulinum toxin A, Ustekinumab biosimilar, Wynzora psoriasis cream).

Short descriptiontext

Hyphens Pharma is a Singapore-headquartered specialty pharmaceutical group that distributes European and US principals' products across 5 ASEAN countries and develops proprietary dermatology brands (Ceradan, TDF, CG 210), serving hospitals, clinics, retail pharmacies and healthcare professionals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, dermatology products, pharmaceutical distribution, ASEAN healthcare market, proprietary dermatological brands
Industry6 codes
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRAOAHAG
Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience)
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Specialty Pharmaceuticals Distribution
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Specialty Pharma Principals
TypeLicensing Royalties
Description

Marketing and selling specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States. Major products include contrast media, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose and Piascledine.

hyphens.com.sg
2Proprietary Brands
TypeOne Time License
Description

Develops, markets and sells proprietary dermatological products under Ceradan and TDF brands, health supplements under Ocean Health brand, and scalp care products under CG 210 brand.

hyphens.com.sg
3Medical Hypermart and Digital
TypeTransaction Fee
Description

Operates medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies to supply pharmaceutical products and medical supplies.

hyphens.com.sg
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Ceradan
Description

Dermatological brand - Complete Emollient Therapy delivering physiological lipids in 3:1:1 ratio for optimum skin barrier repair. Focus on eczema-prone skin conditions.

+4 more records
Core offering1 text field

Hyphens Pharma is a specialty pharmaceutical company that markets and distributes pharmaceutical products across ASEAN through exclusive distribution and licensing agreements with brand principals from Europe and the United States, while also developing, manufacturing, and selling proprietary dermatological brands such as Ceradan, TDF Derma Formula, and CG 210. Its portfolio spans dermatology, ophthalmology, paediatrics, neonatology, allergy, otorhinolaryngology, orthopaedics and rheumatology, radiology, cardiology, and gastroenterology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • TDF Blu Voile Sunscreen provides 82% protection at cellular level against harmful blue light irradiation
+3 more records
Product overview1 text field

Hyphens Pharma is a specialty pharmaceutical company operating as both a distributor of international pharmaceutical brands and a developer of proprietary products. The company distributes specialty pharmaceutical products through exclusive distributorship or licensing agreements with brand principals from Europe and the United States, including products from Bausch + Lomb, Chiesi Farmaceutici, Guerbet Group, HRA Pharma, Lundbeck, and others across therapeutic areas including dermatology, ophthalmology, paediatrics, pulmonology, neuroscience, radiology, and gastroenterology. Additionally, Hyphens Pharma develops and markets proprietary dermatological products under the Ceradan® brand (including Ceradan® Advanced), TDF Derma Formula® brand (including TDF® Blu Voile Sunscreen), and CG 210® brand for hair loss. The company also sells health supplements under the Ocean Health® brand. Products are distributed across Southeast Asia through direct operations in Singapore, Vietnam, Malaysia, Indonesia, and the Philippines.

Product and service10 records
1Ceradan
CategoryProprietary Dermatological Brand
Description

Proprietary dermatological brand featuring Complete Emollient Therapy delivering physiological lipids in the 3:1:1 ratio for optimum skin barrier repair, including skin barrier repair cream and Ceradan Advanced for eczema-prone skin. For healthcare professionals and consumers across ASEAN and Middle East.

2TDF Derma Formula
CategoryProprietary Dermatological Brand
Description

Proprietary dermatological brand including TDF Blu Voile Sunscreen (with clinically-proven 82% blue light protection) and TDF Fairence T-Complex for pigmentation treatment using tranexamic acid, niacinamide, and lactobionic acid. For dermatologists, aesthetic clinics, and patients.

3CG 210
CategoryProprietary Hair Care Brand
Description

Proprietary topical botanical hair growth-promoting agent based on Allium cepa (onion), Citrus medica limonum (lemon), Theobroma cacao (cocoa), and Paullinia cupana (guarana). Safety and efficacy demonstrated in more than 10 clinical studies involving close to 800 subjects. For Singapore and Malaysia markets.

4Meradan Cream
CategoryProprietary Dermatological Brand
Description

Steroid cream containing 0.1% mometasone furoate and physiological lipids including ceramide. Developed with A*STAR using patented microemulsion technology for skin barrier repair. Treats inflammation and itch from eczema, psoriasis, and skin rash. For prescription use in Indonesia and other markets.

5Wynzora Cream
CategoryLicensed Pharmaceutical Product
Description

Leading topical treatment for plaque and scalp psoriasis in adults. Exclusive ASEAN rights from MC2 Therapeutics. Currently also marketed in Italy, Germany, Spain, United Kingdom, and United States.

6Nabota
CategoryLicensed Pharmaceutical Product
Description

Premium high-purity botulinum toxin A (BTA) formulated from Daewoong Pharmaceutical's patented Hi-Pure technology. Licensed for Singapore and Malaysia markets for medical aesthetics and therapeutic applications.

7Ustekinumab Biosimilar
CategoryLicensed Pharmaceutical Product
Description

Human monoclonal antibody targeting interleukin-12 (IL-12) and interleukin-23 (IL-23) for treatment of immune-mediated disorders including plaque psoriasis, psoriatic arthritis, and Crohn's disease. Produced by Alvotech, distributed in Singapore, Malaysia, and Philippines.

8MAGNEZIX
CategoryDistributed Orthopaedic Product
Description

Magnesium alloy metallic implant manufactured by Syntellix AG that can be reabsorbed by the body, enabling quicker and safer bone recovery without need for surgical removal. For orthopaedic surgery in Vietnam.

9Specialty Pharma Principals Distribution Portfolio
CategoryDistributed Specialty Pharmaceuticals
Description

Distribution of specialty pharmaceutical products across dermatology, ophthalmology, paediatrics, neonatology, pulmonology, neuroscience, psychiatry, allergy, otorhinolaryngology, radiology, and cardiology, sourced through exclusive distributorship or licensing and supply agreements with brand principals from Europe and the United States. Includes Besivance, Lotemax, Stérimar, Vivomixx, Fenosup Lidose, Piascledine, Lexapro, Lipiodol, Dotarem, Xenetix, Curosurf, Medikinet MR, Clopixol, Fluanxol, Fluoxetine, D-Cure, Erdomed, Cetraxal, Dorithricin, Rupafin, Liposic, Ocuvite, Monoclarium, and ella.

10Ocean Health
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership25 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-02-01
Description

Partnership to bring Ceradan dermatological brand to Middle East markets including Saudi Arabia, UAE, Kuwait, Qatar and Bahrain for eczema relief products.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Hyphens Pharma awarded exclusive rights to commercialise and supply Wynzora Cream (topical treatment for plaque and scalp psoriasis) and all future product extensions throughout ASEAN. Wynzora is currently marketed in Italy, Germany, Spain, UK and US.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-02-01
Description

License and supply agreement to bring Nabota premium botulinum toxin A to Malaysian and Singapore markets. Nabota uses Daewoong's patented Hi-Pure technology and is the first Asian BTA approved by US FDA with over 1 million treatments in US since 2019.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-12-01
Description

Joint development of Meradan cream with patented microemulsion technology containing mometasone furoate and physiological lipids for skin barrier repair.

5Favorex Pte Ltd (DKSH subsidiary)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-12-01
Description

Exclusive license and supply agreement to commercialise Ustekinumab biosimilar (human monoclonal antibody targeting IL-12 and IL-23) produced by Alvotech in Singapore, Malaysia and Philippines for treatment of plaque psoriasis, psoriatic arthritis and Crohn's disease.

hyphens.com.sg
6JSPharma
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

Exclusive distributor of TDF Fairence T-Complex in South Korea. Key customers include medical clinics, hospitals, and burn centres covering dermatologists, plastic surgeons and aesthetic doctors.

hyphens.com.sg
7Shanghai Good Luck International Trading Co. Ltd.
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-11-01
Description

Exclusive distributor of Ceradan products (except Ceradan Advanced) in Mainland China with integrated marketing capability to sell in medical channel across major economic regions.

hyphens.com.sg
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-06-01
Description

Exclusive distributor for Syntellix AG products in Vietnam, including MAGNEZIX bioabsorbable magnesium alloy metallic implants for bone recovery.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-05-01
Description

Exclusive distribution agreement for marketing and distribution of central nervous system products in Vietnam market. Lundbeck is a global pharmaceutical company specializing in brain disease treatment.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2019-03-01
Description

MoU for R&D collaboration on dermatological products for skin disorders targeting eczema, acne and pigmentary disorders. Builds on prior partnership with A*STAR.

11Doctor Anywhere
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2018-12-01
Description

Entry into Memorandum of Understanding with Doctor Anywhere for potential collaboration in digital healthcare services.

hyphens.com.sg
12A*STAR Institute of Chemical and Engineering Sciences (ICES)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2016-11-01
Description

Licensing of sugar-based surfactant micro-emulsions technology from A*STAR for development of innovative dermatological products. Resulted from Research Collaboration Agreement.

hyphens.com.sg
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Principal partner for eye care products including Besivance and Lotemax.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Principal partner for specialty pharmaceutical products.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Principal partner for contrast media products including Dotarem and Xenetix.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Principal partner for specialty pharmaceutical products including ella emergency contraceptive.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Principal partner for dermatological and consumer healthcare products.

18Laboratoires S.M.B
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Principal partner for specialty pharmaceutical products.

hyphens.com.sg
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Principal partner for specialty pharmaceutical products.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Principal partner for specialty pharmaceutical products including Medikinet for ADHD treatment.

21Next Gen Pharma
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Principal partner for specialty pharmaceutical products.

hyphens.com.sg
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Principal partner for specialty pharmaceutical products.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Principal partner for specialty pharmaceutical products including Rupafin.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Partnership for regulatory, logistics and commercial operations in Indonesia since 2011.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Partnership for regulatory, logistics and commercial operations in Indonesia since 2011.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

French pharmaceutical and dermo-cosmetic company with strong dermatology portfolio and a French/European principal partner model similar to how Hyphens distributes European pharma brands. Overlapping therapeutic focus in dermatology.

TypeRegional player
Description

Singapore-listed healthcare company with proprietary brands (Tiger Balm) and regional distribution. Comparable as a Singapore-listed specialty pharma/consumer health peer of similar scale with regional Asia presence.

TypeBroad incumbent
Description

Global dermatology-focused pharmaceutical company with a broad prescription and aesthetic dermatology portfolio. Relevant because both companies compete in dermatology therapeutics; Galderma is a global incumbent while Hyphens operates regionally.

TypeOthers
Description

Swiss pharmaceutical CDMO that supplies APIs and finished dosage forms to global pharma including dermatology brands. Comparable as an enabling partner within the European-to-Asia pharmaceutical value chain that intersects with Hyphens' principal sourcing model.

TypeDirect peer
Description

One of the largest healthcare distribution groups in Asia, distributing pharmaceuticals and consumer health products across ASEAN markets. Direct comparable to Hyphens' Principals and Medical Hypermart segments given overlapping customer base and similar distribution contracts with global pharma principals.

TypeBroad incumbent
Description

Global specialty pharma company focused on dermatology (psoriasis, eczema, actinic keratosis). Comparable therapeutic-area focus to Hyphens' proprietary brands; LEO is a multinational incumbent while Hyphens is regional.

TypeDirect peer
Description

Swiss-listed market expansion services group with the largest healthcare distribution platform in ASEAN. Both companies operate as principal intermediaries distributing Western pharma brands across Southeast Asia, with overlapping regional coverage and similar go-to-market models.

TypeRegional player
Description

South Korea-listed pharmaceutical company with branded prescription and OTC products including dermatology offerings. Comparable as an Asia-headquartered specialty pharma player with both proprietary and distribution-style operations.

TypeBroad incumbent
Description

Global consumer health major with a substantial dermatology and skincare portfolio. Comparable as a principal-style brand owner that competes with Hyphens' distributed and proprietary dermatology brands.

TypeRegional player
Description

Philippines-listed pharmaceutical company manufacturing and distributing branded generics and consumer health products in ASEAN. Comparable as a regional pharma player with similar distribution-led model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hyphens Pharma

Specialty Pharmaceuticals Distributionhyphens.com.sg

Hyphens Pharma is a Singapore-headquartered specialty pharmaceutical group that distributes European and US principals' products across 5 ASEAN countries and develops proprietary dermatology brands (Ceradan, TDF, CG 210), serving hospitals, clinics, retail pharmacies and healthcare professionals.

What Hyphens Pharma does

Hyphens Pharma Pte Ltd is a Singapore-headquartered specialty pharmaceutical group (parent: Hyphens Pharma International Limited; SGX Catalist: 1J5) that operates across 5 directly-served ASEAN markets (Singapore, Malaysia, Vietnam, Indonesia, Philippines) and reaches a further 10 countries via distribution partners, with a field force of approximately 330 sales and marketing professionals. The group runs three business pillars: (i) Specialty Pharma Principals — exclusive distribution, licensing and supply agreements with European and US brand principals (including Bausch+Lomb, Chiesi, Guerbet, HRA Pharma, Lundbeck, MEDICE, Daewoong, and others) covering therapeutic areas such as dermatology, ophthalmology, paediatrics, neonatology, allergy, otorhinolaryngology, orthopaedics and rheumatology, radiology, cardiology, gastroenterology, and child psychiatry; (ii) Proprietary Brands — developed, marketed and sold dermatological products under the Ceradan (including patented Ceradan Advanced pH Management) and TDF Derma Formula lines, scalp-care products under CG 210 (acquired from Legacy Healthcare), and health supplements under Ocean Health, with several technologies (Meradan microemulsion, Xcelarev delivery, Hi-Pure botulinum toxin A) co-developed or licensed with A*STAR; and (iii) Medical Hypermart and Digital — operated through DocMed Technology, supplying pharmaceutical products and medical supplies to healthcare professionals, institutions and retail pharmacies. Founded with early operations in Vietnam in 1989, the group has subsequently expanded to Malaysia (2004), Philippines (2007), Indonesia (2011), and into Middle East markets via a Cooper Pharma partnership for Ceradan in 2024 and an exclusive MC2 Therapeutics licence for Wynzora Cream across ASEAN in 2024. Reported group revenue was SGD 162.3 million in 2022.

The business model combines licensing/royalty economics on distributed principals, branded OTC/Rx product economics on proprietary dermatology and supplement lines, and B2B transaction fees through the DocMed medical hypermart. Go-to-market is enterprise field sales targeting hospitals, clinics, retail pharmacies and healthcare professionals across Southeast Asia, supplemented by exclusive third-party distributors in non-direct markets such as Mainland China, South Korea and the Middle East. Proprietary product differentiation relies on patented formulation technologies, clinical study evidence (e.g., Ceradan Advanced pH-control mechanism, TDF Blu Voile sunscreen cellular-level blue light protection, Meradan co-developed microemulsion), and trademarks granted across multiple jurisdictions. Strategic R&D is conducted through ongoing collaborations with A*STAR (ICES and A*ccelerate units) on microemulsion and dermatological R&D, while licensing-led growth has been the principal route for pipeline additions (Nabota botulinum toxin A, Ustekinumab biosimilar, Wynzora psoriasis cream).

Hyphens Pharma firmographics

Firmographics
Name
Hyphens Pharma
Legal name
Hyphens Pharma Pte Ltd
Website
https://hyphens.com.sg
Company type
Public
Founded year
1989
Operating status
Operating
Headcount range
251–500 employees
Short description
Hyphens Pharma is a Singapore-headquartered specialty pharmaceutical group that distributes European and US principals' products across 5 ASEAN countries and develops proprietary dermatology brands (Ceradan, TDF, CG 210), serving hospitals, clinics, retail pharmacies and healthcare professionals.
Ownership category
akta.pro rank

Hyphens Pharma industry classification

Industry
Product category
Specialty Pharmaceuticals Distribution
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRAOAHAG
Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience)
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Dermatology products
  • Pharmaceutical distribution
  • ASEAN healthcare market
  • Proprietary dermatological brands

Where Hyphens Pharma is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices6 records

Markets served

Hyphens Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations

Revenue model

  1. Specialty Pharma Principals: Marketing and selling specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States. Major products include contrast media, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose and Piascledine.
  2. Proprietary Brands: Develops, markets and sells proprietary dermatological products under Ceradan and TDF brands, health supplements under Ocean Health brand, and scalp care products under CG 210 brand.
  3. Medical Hypermart and Digital: Operates medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies to supply pharmaceutical products and medical supplies.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Hyphens Pharma product offering

Product offering

Core offering

Hyphens Pharma is a specialty pharmaceutical company that markets and distributes pharmaceutical products across ASEAN through exclusive distribution and licensing agreements with brand principals from Europe and the United States, while also developing, manufacturing, and selling proprietary dermatological brands such as Ceradan, TDF Derma Formula, and CG 210. Its portfolio spans dermatology, ophthalmology, paediatrics, neonatology, allergy, otorhinolaryngology, orthopaedics and rheumatology, radiology, cardiology, and gastroenterology.

Product overview

Hyphens Pharma is a specialty pharmaceutical company operating as both a distributor of international pharmaceutical brands and a developer of proprietary products. The company distributes specialty pharmaceutical products through exclusive distributorship or licensing agreements with brand principals from Europe and the United States, including products from Bausch + Lomb, Chiesi Farmaceutici, Guerbet Group, HRA Pharma, Lundbeck, and others across therapeutic areas including dermatology, ophthalmology, paediatrics, pulmonology, neuroscience, radiology, and gastroenterology. Additionally, Hyphens Pharma develops and markets proprietary dermatological products under the Ceradan® brand (including Ceradan® Advanced), TDF Derma Formula® brand (including TDF® Blu Voile Sunscreen), and CG 210® brand for hair loss. The company also sells health supplements under the Ocean Health® brand. Products are distributed across Southeast Asia through direct operations in Singapore, Vietnam, Malaysia, Indonesia, and the Philippines.

Differentiator

Problem solved

Functional benefit

Brands

  • Ceradan: Dermatological brand - Complete Emollient Therapy delivering physiological lipids in 3:1:1 ratio for optimum skin barrier repair. Focus on eczema-prone skin conditions.
  • TDF Derma Formula
  • CG 210
  • Ocean Health
  • DocMed Technology

Products and services

  • Ceradan Proprietary dermatological brand featuring Complete Emollient Therapy delivering physiological lipids in the 3:1:1 ratio for optimum skin barrier repair, including skin barrier repair cream and Ceradan Advanced for eczema-prone skin. For healthcare professionals and consumers across ASEAN and Middle East.
  • TDF Derma Formula Proprietary dermatological brand including TDF Blu Voile Sunscreen (with clinically-proven 82% blue light protection) and TDF Fairence T-Complex for pigmentation treatment using tranexamic acid, niacinamide, and lactobionic acid. For dermatologists, aesthetic clinics, and patients.
  • CG 210 Proprietary topical botanical hair growth-promoting agent based on Allium cepa (onion), Citrus medica limonum (lemon), Theobroma cacao (cocoa), and Paullinia cupana (guarana). Safety and efficacy demonstrated in more than 10 clinical studies involving close to 800 subjects. For Singapore and Malaysia markets.
  • Meradan Cream Steroid cream containing 0.1% mometasone furoate and physiological lipids including ceramide. Developed with A*STAR using patented microemulsion technology for skin barrier repair. Treats inflammation and itch from eczema, psoriasis, and skin rash. For prescription use in Indonesia and other markets.
  • Wynzora Cream Leading topical treatment for plaque and scalp psoriasis in adults. Exclusive ASEAN rights from MC2 Therapeutics. Currently also marketed in Italy, Germany, Spain, United Kingdom, and United States.
  • Nabota Premium high-purity botulinum toxin A (BTA) formulated from Daewoong Pharmaceutical's patented Hi-Pure technology. Licensed for Singapore and Malaysia markets for medical aesthetics and therapeutic applications.
  • Ustekinumab Biosimilar Human monoclonal antibody targeting interleukin-12 (IL-12) and interleukin-23 (IL-23) for treatment of immune-mediated disorders including plaque psoriasis, psoriatic arthritis, and Crohn's disease. Produced by Alvotech, distributed in Singapore, Malaysia, and Philippines.
  • MAGNEZIX Magnesium alloy metallic implant manufactured by Syntellix AG that can be reabsorbed by the body, enabling quicker and safer bone recovery without need for surgical removal. For orthopaedic surgery in Vietnam.
  • Specialty Pharma Principals Distribution Portfolio Distribution of specialty pharmaceutical products across dermatology, ophthalmology, paediatrics, neonatology, pulmonology, neuroscience, psychiatry, allergy, otorhinolaryngology, radiology, and cardiology, sourced through exclusive distributorship or licensing and supply agreements with brand principals from Europe and the United States. Includes Besivance, Lotemax, Stérimar, Vivomixx, Fenosup Lidose, Piascledine, Lexapro, Lipiodol, Dotarem, Xenetix, Curosurf, Medikinet MR, Clopixol, Fluanxol, Fluoxetine, D-Cure, Erdomed, Cetraxal, Dorithricin, Rupafin, Liposic, Ocuvite, Monoclarium, and ella.
  • Ocean Health

Quantifiable outcome

  • TDF Blu Voile Sunscreen provides 82% protection at cellular level against harmful blue light irradiation
  • +3 more outcomes

Companies that use Hyphens Pharma

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Hyphens Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Hyphens Pharma partnerships and signals

Strategic signal

Partnerships

25 partnerships are on record, tiered core, strategic and regional.

  • Cooper PharmacoreChannel Partner/ Reseller/ Distributor · 1 February 2024Partnership to bring Ceradan dermatological brand to Middle East markets including Saudi Arabia, UAE, Kuwait, Qatar and Bahrain for eczema relief products.
  • MC2 TherapeuticscoreChannel Partner/ Reseller/ Distributor · 1 January 2024Hyphens Pharma awarded exclusive rights to commercialise and supply Wynzora Cream (topical treatment for plaque and scalp psoriasis) and all future product extensions throughout ASEAN. Wynzora is currently marketed in Italy, Germany, Spain, UK and US.
  • Daewoong PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 1 February 2023License and supply agreement to bring Nabota premium botulinum toxin A to Malaysian and Singapore markets. Nabota uses Daewoong's patented Hi-Pure technology and is the first Asian BTA approved by US FDA with over 1 million treatments in US since 2019.
  • A*STAR (Agency for Science, Technology and Research)strategicStrategic or Co-development Partner · 1 December 2022Joint development of Meradan cream with patented microemulsion technology containing mometasone furoate and physiological lipids for skin barrier repair.
  • Favorex Pte Ltd (DKSH subsidiary)coreChannel Partner/ Reseller/ Distributor · 1 December 2021Exclusive license and supply agreement to commercialise Ustekinumab biosimilar (human monoclonal antibody targeting IL-12 and IL-23) produced by Alvotech in Singapore, Malaysia and Philippines for treatment of plaque psoriasis, psoriatic arthritis and Crohn's disease.
  • JSPharmaregionalChannel Partner/ Reseller/ Distributor · 1 January 2021Exclusive distributor of TDF Fairence T-Complex in South Korea. Key customers include medical clinics, hospitals, and burn centres covering dermatologists, plastic surgeons and aesthetic doctors.
  • Shanghai Good Luck International Trading Co. Ltd.regionalChannel Partner/ Reseller/ Distributor · 1 November 2020Exclusive distributor of Ceradan products (except Ceradan Advanced) in Mainland China with integrated marketing capability to sell in medical channel across major economic regions.
  • Syntellix AGregionalChannel Partner/ Reseller/ Distributor · 1 June 2019Exclusive distributor for Syntellix AG products in Vietnam, including MAGNEZIX bioabsorbable magnesium alloy metallic implants for bone recovery.
  • LundbeckcoreChannel Partner/ Reseller/ Distributor · 1 May 2019Exclusive distribution agreement for marketing and distribution of central nervous system products in Vietnam market. Lundbeck is a global pharmaceutical company specializing in brain disease treatment.
  • A*STAR A*cceleratestrategicStrategic or Co-development Partner · 1 March 2019MoU for R&D collaboration on dermatological products for skin disorders targeting eczema, acne and pigmentary disorders. Builds on prior partnership with A*STAR.
  • Doctor AnywherestrategicStrategic or Co-development Partner · 1 December 2018Entry into Memorandum of Understanding with Doctor Anywhere for potential collaboration in digital healthcare services.
  • A*STAR Institute of Chemical and Engineering Sciences (ICES)strategicStrategic or Co-development Partner · 1 November 2016Licensing of sugar-based surfactant micro-emulsions technology from A*STAR for development of innovative dermatological products. Resulted from Research Collaboration Agreement.
  • Bausch + LombcoreChannel Partner/ Reseller/ DistributorPrincipal partner for eye care products including Besivance and Lotemax.
  • Chiesi Farmaceutici S.p.A.coreChannel Partner/ Reseller/ DistributorPrincipal partner for specialty pharmaceutical products.
  • Guerbet GroupcoreChannel Partner/ Reseller/ DistributorPrincipal partner for contrast media products including Dotarem and Xenetix.
  • HRA PharmacoreChannel Partner/ Reseller/ DistributorPrincipal partner for specialty pharmaceutical products including ella emergency contraceptive.
  • Laboratoires ExpansciencecoreChannel Partner/ Reseller/ DistributorPrincipal partner for dermatological and consumer healthcare products.
  • Laboratoires S.M.BcoreChannel Partner/ Reseller/ DistributorPrincipal partner for specialty pharmaceutical products.
  • Laboratorios SALVAT S.A.coreChannel Partner/ Reseller/ DistributorPrincipal partner for specialty pharmaceutical products.
  • MEDICE Arzneimittel Putter GmbH & Co KGcoreChannel Partner/ Reseller/ DistributorPrincipal partner for specialty pharmaceutical products including Medikinet for ADHD treatment.
  • Next Gen PharmacoreChannel Partner/ Reseller/ DistributorPrincipal partner for specialty pharmaceutical products.
  • Sofibel - Laboratoires Fumouze (Church & Dwight Group)coreChannel Partner/ Reseller/ DistributorPrincipal partner for specialty pharmaceutical products.
  • UriachcoreChannel Partner/ Reseller/ DistributorPrincipal partner for specialty pharmaceutical products including Rupafin.
  • P.T. Nicholas LaboratoriesregionalChannel Partner/ Reseller/ DistributorPartnership for regulatory, logistics and commercial operations in Indonesia since 2011.
  • P.T. Kebayoran PharmaregionalChannel Partner/ Reseller/ DistributorPartnership for regulatory, logistics and commercial operations in Indonesia since 2011.

Scale indicators6 records

Recent moves9 records

Expansion highlights7 records

Hyphens Pharma competitors and assessment

Company assessment

Broad incumbents

  • Pierre Fabre: French pharmaceutical and dermo-cosmetic company with strong dermatology portfolio and a French/European principal partner model similar to how Hyphens distributes European pharma brands. Overlapping therapeutic focus in dermatology.
  • Galderma: Global dermatology-focused pharmaceutical company with a broad prescription and aesthetic dermatology portfolio. Relevant because both companies compete in dermatology therapeutics; Galderma is a global incumbent while Hyphens operates regionally.
  • LEO Pharma: Global specialty pharma company focused on dermatology (psoriasis, eczema, actinic keratosis). Comparable therapeutic-area focus to Hyphens' proprietary brands; LEO is a multinational incumbent while Hyphens is regional.
  • Bayer Consumer Health (Dermatology): Global consumer health major with a substantial dermatology and skincare portfolio. Comparable as a principal-style brand owner that competes with Hyphens' distributed and proprietary dermatology brands.

Regional players

  • Haw Par Corporation: Singapore-listed healthcare company with proprietary brands (Tiger Balm) and regional distribution. Comparable as a Singapore-listed specialty pharma/consumer health peer of similar scale with regional Asia presence.
  • Yuhan Corporation: South Korea-listed pharmaceutical company with branded prescription and OTC products including dermatology offerings. Comparable as an Asia-headquartered specialty pharma player with both proprietary and distribution-style operations.
  • EuroMed Laboratories Philippines: Philippines-listed pharmaceutical company manufacturing and distributing branded generics and consumer health products in ASEAN. Comparable as a regional pharma player with similar distribution-led model.

Others

  • Siegfried Holding: Swiss pharmaceutical CDMO that supplies APIs and finished dosage forms to global pharma including dermatology brands. Comparable as an enabling partner within the European-to-Asia pharmaceutical value chain that intersects with Hyphens' principal sourcing model.

Direct peers

  • Zuellig Pharma: One of the largest healthcare distribution groups in Asia, distributing pharmaceuticals and consumer health products across ASEAN markets. Direct comparable to Hyphens' Principals and Medical Hypermart segments given overlapping customer base and similar distribution contracts with global pharma principals.
  • DKSH Holding: Swiss-listed market expansion services group with the largest healthcare distribution platform in ASEAN. Both companies operate as principal intermediaries distributing Western pharma brands across Southeast Asia, with overlapping regional coverage and similar go-to-market models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Hyphens Pharma social profiles

Digital presence

Hyphens Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hyphens Pharma leadership team

Management profile

Number of profiles

Profiles13 records

Hyphens Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Hyphens Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hyphens Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hyphens Pharma

What does Hyphens Pharma do?

Hyphens Pharma is a specialty pharmaceutical company that markets and distributes pharmaceutical products across ASEAN through exclusive distribution and licensing agreements with brand principals from Europe and the United States, while also developing, manufacturing, and selling proprietary dermatological brands such as Ceradan, TDF Derma Formula, and CG 210. Its portfolio spans dermatology, ophthalmology, paediatrics, neonatology, allergy, otorhinolaryngology, orthopaedics and rheumatology, radiology, cardiology, and gastroenterology.

Is Hyphens Pharma a public or private company?

Hyphens Pharma is a public company. It is classified as public and is currently operating.

When was Hyphens Pharma founded?

Hyphens Pharma was founded in 1989. It employs 251 to 500 people.

Where is Hyphens Pharma based?

Hyphens Pharma is headquartered in Singapore, Singapore, in the Asia region.

How does Hyphens Pharma make money?

Three revenue lines are on record. Specialty Pharma Principals are the primary driver. The others are proprietary Brands and medical Hypermart and Digital.

Who are Hyphens Pharma's main competitors?

Broad incumbents on record are Pierre Fabre, Galderma, LEO Pharma and Bayer Consumer Health (Dermatology). Regional players are Haw Par Corporation, Yuhan Corporation and EuroMed Laboratories Philippines. Siegfried Holding is listed as an others. Direct peers are Zuellig Pharma and DKSH Holding.

Does Hyphens Pharma have an API?

No public API is recorded for Hyphens Pharma.

What industry is Hyphens Pharma in?

Hyphens Pharma's product category is Specialty Pharmaceuticals Distribution. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals